

Irisin may be involved in exendin-4 mitochondrial action in human adipocytes

Agnieszka Dziewońska, Anna Polus, Anna Gruca, Bogdan Solnica, Joanna Góralska*

Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland

Submitted: 4 July 2025; **Accepted:** 25 November 2025

Online publication: 3 April 2026

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/214730>

Copyright © 2026 Termedia & Banach

***Corresponding author:**

Joanna Góralska
Department of
Clinical Biochemistry
Jagiellonian University
Medical College
Krakow, Poland
E-mail: j.goralska@uj.edu.pl

Abstract

Introduction: Disturbed mitochondrial activity in adipocytes has been proposed as one of the mechanisms involved in metabolic dysfunction in obesity. Glucagon-like peptide receptor agonists (GLP-1RAs) are used to normalize glucose level and reduce body weight. GLP-1 activates intracellular pathways similar to those of irisin, a peptide that modulates metabolism by stimulating the 'browning' of adipocytes. The aim of the study was to investigate the mechanisms of action of the GLP-1RA exendin-4 at the mRNA, protein, and mitochondrial levels in human adipocytes.

Material and methods: Human Chub-S7 preadipocytes were differentiated *in vitro* to mature adipocytes and then stimulated with exendin-4 at 100 nM for 24 h. Expression levels of mRNA and proteins (irisin, adiponectin, visfatin/NAMPT) were measured. Oxygen consumption rates and intracellular ATP content were determined.

Results: Exendin-4 enhanced the secretion of irisin and visfatin by adipocytes. Upregulated expression of FNDC5, NAMPT, and UCP2 genes was accompanied by modest changes in mitochondrial activity in exendin-4-treated adipocytes. Exendin-4 exerted a similar effect on mitochondrial oxygen consumption rates as irisin, including increased maximum mitochondrial respiration and reserve capacity with unchanged intracellular ATP.

Conclusions: Increasing energy expenditure by exendin-4 may be associated with upregulation of irisin in human adipocytes. Clinical studies are necessary to confirm the hypothesis that nutrients, by stimulating the secretion of GLP-1, may influence the expression of irisin and thus modulate the mitochondrial metabolism of adipocytes.

Key words: obesity, irisin, mitochondria, mitochondrial dysfunction, adipocyte, exendin-4, GLP-1RA, browning of WAT.

Introduction

Obesity is a global pandemic, with profound clinical, social, and economic consequences [1]. It is a complex, metabolic disease resulting from the expansion of adipose tissue, which depends on the interplay between hyperplasia (proliferation and differentiation of adipose precursor cells) and hypertrophy (increase in adipocyte size) [2]. Recent studies indicate that mitochondrial dysfunction caused by excessive nutrient supply that overwhelms the Krebs cycle and the mitochondrial respiratory chain may be associated with the development of obesity, oxidative stress, and inflammation [3, 4]. Prevention of mitochondrial dysfunction is a potential tool to combat obesity.

Among the factors influencing mitochondrial activity and adipocyte metabolism, the adipomyokine irisin has been clearly associated with an increase in energy expenditure due to its ability to stimulate the browning of white adipose tissue (WAT) [5]. Browning of WAT is a process of trans-differentiation from white to beige adipocytes, involving mitochondrial biogenesis, uncoupling of the mitochondrial respiratory chain and switch from energy accumulation to energy dissipation. Thus, strategies aimed at promoting WAT browning may have great potential to improve metabolism and treat obesity, due to the ability of brown adipose tissue (BAT) to dissipate energy through thermogenesis [6]. Recent studies have shown that irisin levels, in addition to physical activity, can also be influenced by diet and certain specific drugs (such as metformin, fenofibrate, and all-trans retinoic acid) [7]. Irisin exerts beneficial effects on energy homeostasis [8], reduces systemic inflammation [9], modulates metabolic processes [10], and increases the whole body metabolic rate by inducing glucose transporter 4 (GLUT-4) expression and stimulating glycolysis in adipocytes [11].

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are known incretin hormones in humans, released predominantly in the intestine [12]. These hormones are secreted in response to nutrient intake and stimulate insulin secretion from the pancreas [13]. GLP-1 exerts its effects through the GLP-1 receptor (GLP-1R) in multiple tissues, including the pancreas, kidneys, adipose tissue, brain, and smooth muscles [14]. GLP-1, besides its role in glucose homeostasis, reduces appetite, food intake, and body weight [15]. Due to the short half-life of native GLP-1, GLP-1 receptor agonists (GLP-1RAs) have been developed for therapeutic purposes, such as exendin-4, introduced for the treatment of type 2 diabetes (T2D) in the mid-2000s [16]. Over the last decade, GLP-1RA has also gained considerable attention as an effective anti-obesity agent [17–19].

Obese patients with type 2 diabetes treated with exenatide have been shown to have significantly increased irisin levels, which correlated with improved metabolic profiles [20], thus suggesting a possible interaction between irisin and incretin hormones. In addition, both the GLP-1 insulinotropic effects and irisin levels are defective in T2D, and their exogenous administration is able to improve glycemic control [21, 22]. Furthermore, some researchers suggest that irisin can be considered an incretin hormone because its secretion is influenced by meals and increases insulin secretion in a glucose-dependent manner [23]. Thus, both peptides share direct pancreatic effects. Re-

cent studies suggested that, albeit through different receptor pathways, irisin and GLP-1 activate the same intracellular signaling proteins, e.g. PI-3K, AKT, CREB, and ERK1/2 [23].

Based on these reports, the aim of the study was to investigate the effect of exendin-4 on mitochondrial function in human preadipocytes, as well as on selected adipokines and irisin secretion. Additionally, expression of the FNDC5 gene as a precursor of irisin and the NAMPT gene as a precursor of visfatin was examined to validate the results of irisin and visfatin protein secretion.

Material and methods

Cell culture

Chub-S7 is an immortalized cell line provided by Nestle Research Center (Lausanne, Switzerland). These cells, derived from subcutaneous abdominal adipose tissue, preserved their adipogenic capacity and can differentiate into mature adipocytes [24]. The Chub-S7 cells (Nestle Research Center, Lausanne, Switzerland) were cultured in a mixture of DMEM/Ham's F12 1 : 1 (Sigma) supplemented with 10% fetal bovine serum (Sigma). The cells were incubated in a basal medium consisting of serum-free DMEM/F12 medium, supplemented with 17 μ M D-pantothenic acid (Sigma), 33 μ M d-biotin (Sigma), 5 μ g/ml transferrin (Sigma), 1 nM triiodothyronine (Sigma), 5 μ g/ml insulin (Sigma), 500 μ g/ml fetuin (Sigma), and 5 ng/ml selenium (Sigma). The Chub-S7 cells were differentiated into mature adipocytes by adding 1 μ M dexamethasone (Sigma) and 1 μ M rosiglitazone (Cayman). For the first 48 h of differentiation, 500 μ M IBMX (Sigma) was additionally added. The differentiation process lasted 21 days. The differentiated adipocytes were exposed to the following factors for 24 h: irisin (250 ng/ml) or GLP-1R agonist exendin-4 (Ex-4) (100 nM) or GLP-1R antagonist exendin-9 (Ex-9) (100 nM).

Oil-Red-O staining

In order to assess the differentiation of Chub-S7 adipocytes, lipid droplets in cells were stained with red oil dye. The cells were fixed using a 4% solution of paraformaldehyde (POCH, Gliwice, Poland) and then incubated for 1 h with red oil dye (Sigma), according to the protocol provided by the manufacturer. Next, these cells were visualized under a Nikon ECLIPSE TS100 microscope.

Protein secretion

Irisin, visfatin/NAMPT, and adiponectin levels in the culture medium/cell lysate were measured using enzyme-linked immunosorbent assay (ELISA).

Irisin levels were measured using an Irisin ELISA Kit (limit of quantification [LoQ] – 1 ng/ml; BioVendor-Research and Diagnostic Products, Brno, Czech Republic). Human visfatin (NAMPT) (Intra-Cellular) ELISA Kit (LoQ – 30 pg/ml; BioVendor-Research and Diagnostic Products, Brno, Czech Republic) was used to measure visfatin levels. For visfatin determinations, 10× diluted culture medium was used, and for intracellular NAMPT determinations, 1000× diluted cell lysate was used. Results from NAMPT were calculated with Magellan 6 software as pg NAMPT and then adjusted for protein content and reported as pg NAMPT/μg of cell protein. Protein content was measured in the cell lysate samples using a Total Protein Kit, Micro Lowry, Peterson's Modification (Sigma). Adiponectin was measured using a Human Total Adiponectin/Acrp30 ELISA Kit (LoQ – 0.891 ng/ml; Bio-Techne, R&D Systems, USA). All the steps were performed strictly in accordance with the kit instructions.

Relative gene expression

The quantitative expression analysis of *UCP1*, *UCP2* (uncoupling proteins), *NAMPT* (nicotinamide phosphoribosyltransferase), and *FNDC5* (fibronectin type III domain-containing protein 5) was performed by real-time PCR using *18S rRNA* (*Hs03003631_g1*) (*Applied Biosystems*) as the reference gene.

Following incubation, total RNA was isolated from cells using the TRIzol Plus RNA Purification System (Life Technologies, Carlsbad, CA, USA). The quality of RNA was assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). One microgram of total RNA was reverse transcribed using a reverse transcription kit (High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) with random primers. Subsequently, cDNA was subjected to real-time PCR. Quantitative real-time polymerase chain reaction (qPCR) was performed with TaqMan Gene Expression Assays, according to the manufacturer's protocol using TaqMan primers for *UCP1* (*Hs00222453_m1*), *UCP2* (*Hs01075227_m1*), *NAMPT* (*Hs00237184_m1*), and *FNDC5* (*Hs00401006_m1*) (Applied Biosystems, Carlsbad, CA, USA). Amplification was performed using the continuous fluorescence detection system 7900 HT Fast Real Time PCR system (Applied Biosystems, Carlsbad, CA, USA). Data were obtained in a form of sigmoid amplification plots in which fluorescence was plotted against the number of cycles. The threshold cycle (CT) served as a measurement of the starting template amount in each sample. Expression ratio was calculated as the normalized CT difference between the control probe and the sample.

Oxygen consumption

Mitochondrial respiration was determined by high-resolution respirometry using an Oxygraph-2k (O2k; OROBOROS Instruments, Austria, Innsbruck) according to the phosphorylation control protocol for intact cells [25]. For respirometric analysis, cells were cultured in 25 cm² flasks, trypsinized and counted in a Bürker chamber. Then, the cell suspension was diluted with cultured medium to an appropriate concentration of 10⁶ cells/ml and 2 ml samples of cell suspension were added to the Oxygraph chambers. The protocol according to Dunham-Snary *et al.* [26] was used. The following working concentrations for each mitochondrial effector were selected: 2 μg/ml oligomycin, 0.5–3.0 μM FCCP (p-trifluoromethoxy carbonyl cyanide phenyl hydrazine), 12 μM antimycin A (AA), and 3 μM rotenone (Rote). Before each experiment, the polarographic oxygen sensors (OroboPOS, POS) were calibrated by a two-point calibration, routinely achieved at air saturation and zero oxygen concentration according to the protocol described by Gnaiger *et al.* [27]. Accordingly, static calibration involved the determination of the constant signal of the POS recorded at 100% and 0% air saturation (achieved with Na-dithionite, OroboPOS-Service Kit) under the particular experimental conditions (temperature, signal amplification by electronic gain, polarization voltage, stirring speed, medium). The procedure used for background correction has been described in detail by Gnaiger *et al.* [28].

The protocol for oxygen consumption rate (OCR) measurement in the intact cells included in sequence: (I) a short period of routine respiration (routine), reflecting the aerobic metabolic activity under cellular routine conditions; (II) oligomycin, which is an ATP synthase inhibitor and blocks oxidative phosphorylation and the electron transport chain; (III) FCCP titration, which yields the maximum stimulated respiration, as a measure of electron transport system capacity of uncoupled mitochondria; (IV) antimycin A – an inhibitor of mitochondrial respiratory complex III – and rotenone – an inhibitor of mitochondrial respiratory complex I. Cellular bioenergetic parameters including ATP- and non-ATP-linked oxygen consumption as well as maximal oxygen consumption and reserve capacity were calculated (Figure 1).

Intracellular ATP content

The intracellular ATP content was measured using the ATPlite Luminescence ATP Detection Assay System (Perkin Elmer, Waltham, MA, USA), according to the protocol provided by the manufacturer, and the luminescence was measured using a Tecan Genios microplate reader (Thermo Fisher). Re-




Figure 1. Example trace from oxygen consumption rate (OCR) of Chub-S7 cells, illustrating bioenergetic parameters including basal respiration, ATP-linked respiration, non-ATP-linked respiration, maximal oxygen consumption, reserve capacity, and non-mitochondrial respiration

sults were calculated with Magellan 6 software as nmol ATP and then normalized for protein content in the sample. Protein content was measured in the samples of cell lysates using a Total Protein Kit, Micro Lowry, Peterson's Modification (Sigma). Finally, results were reported as nmol ATP/mg of cell protein.

Statistical analysis

All data were expressed as the mean \pm S.D. from three independent experiments (biological replicates) measured in technical triplicates. Statistical significance for comparisons between treated and control cell samples was determined by the unpaired *t*-test using Statistica 10.0 PL software.




Figure 2. Cell model: **A** – Chub-S7 cells prior to differentiation; **B** – Chub-S7 cells after 21 days of differentiation into mature adipocytes; **C** – Chub-S7 after 21 days of differentiation with lipid droplets stained by Oil Red-O; magnification 200 \times




Figure 3. (A) Irisin, (B) adiponectin, (C) visfatin, and (D) NAMPT were measured by enzyme-linked immunosorbent assay (ELISA) in cell culture supernatant (A, B, C) or cell lysate (D) after exposure to exendin-4 (Ex-4) (100 nM, 24 h) or exendin-4 (100 nM, 24 h) along with exendin-9 (100 nM, 24 h) (Ex-4 + Ex-9). Values are presented as mean + SD ($n = 3$) and were analyzed using a t -test; * $p < 0.05$ compared to control

Results

Cell differentiation

Changes in morphology of Chub-S7 cells and lipid droplet accumulation were observed using light microscopy. After 21 days of differentiation, the cells were stained with Oil Red-O. The lipid droplets in the cells turned red (Figure 2), which confirmed that preadipocytes differentiated into mature, functional adipocytes, used for further research.

Protein secretion

Analysis of protein secretion indicated that Chub-S7 cells exposed to Ex-4 released significantly more irisin (Figure 3 A) and visfatin (Figure 3 C) to cell culture supernatant and presented a higher intracellular NAMPT level than control cells (Figure 3 D). In the case of adiponectin, no significant changes were observed in Chub-S7 cells incubated with Ex-4 (Figure 3 B). To confirm the specificity of effects exerted by Ex-4 in Chub-S7 cells, the experiments were repeated using 100 nM exendin-9, a GLP-1 receptor antagonist, which reverted the effects of Ex-4 on protein secretion.

Gene expression

Selected genes were examined: (i) genes related to mitochondrial uncoupling (*UCP1*, *UCP2*), (ii) the gene encoding transmembrane protein fibronectin type III domain-containing protein 5 precursor of irisin (*FNDC5*), and (iii) the gene involved in NAD^+ synthesis (*NAMPT*) (Figure 4). The




Figure 4. Changes in relative gene expression of selected genes: *UCP1*, *UCP2*, *FNDC5* and *NAMPT*. As a reference gene, expression of 18S r-RNA was used. Values are presented as mean +SD ($n = 3$) and were analyzed using a t -test; * $p < 0.05$ compared to control

Table I. Oxygen consumption rates (OCR) measured by high resolution respirometry in Chub-S7 cells

Parameter	Control	Irisin	Ex-4	Ex-4 + Ex-9
Basal OCR	24.80 ±2.25	30.67 ±5.51	29.08 ±9.28	26.08 ±4.64
Routine mitochondrial	18.60 ±1.99	25.67 ±4.16	24.58 ±5.30	19.70 ±0.64
Maximum	47.47 ±8.83	65.00 ±6.08	62.81 ±7.83	52.80 ±15.35
Non-mitochondrial	6.20 ±3.34	4.17 ±3.55	4.50 ±4.36	6.37 ±5.07
Maximum mitochondrial	41.27 ±6.07	59.67 ±4.16	58.31 ±3.77	41.76 ±6.19
Non-ATP-linked	7.75 ±9.15	11.67 ±2.52	11.72 ±3.96	6.61 ±2.54
ATP-linked	10.84 ±7.82	11.33 ±4.04	11.86 ±5.01	10.18 ±7.33
Reserve capacity	22.68 ±6.61	34.33 ±2.08	33.73 ±1.54	24.21 ±8.10

Data are presented as mean ± standard deviation. All values in pmol/min. Ex-4 – exendin-4, Ex-4 + Ex-9 – exendin-4 + exendin-9.

expression of *UCP* genes is related to discharge of the proton gradient that is generated by the mitochondrial respiratory chain. The *UCP2* gene was upregulated in Chub-S7 cells incubated with Ex-4, while the expression of the *UCP1* gene only tended to be slightly increased in Ex-4 treated cells. Ex-4 increased more than threefold the expression of the *FNDC5* gene, coding for irisin, and *NAMPT*, coding for a key nicotinamide adenine dinucleotide (NAD) biosynthetic enzyme in mammals. Exendin-9 abolished these effects of GLP-1 receptor agonist, thus confirming that they were related to Ex-4.

Oxygen consumption

Mitochondrial respiration was analyzed by high-resolution respirometry using an Oxygraph-2k system.

Exploratory observations of oxygen consumption revealed differences between cells treated with irisin or Ex-4 and control cells. The addition of exendin-9 together with Ex-4 abolished the effect of GLP-1RA (Table I).

Basal OCR was slightly increased in irisin treated cells (Figure 5 A). When the non-mitochondrial oxygen consumption, measured after full inhibition of mitochondrial electron transport chain by antimycin A and rotenone, was subtracted, the routine mitochondrial respiration was increased in the irisin and Ex-4 treated cells. ATP-linked oxygen consumption, calculated as the difference between basal oxygen consumption and OCR measured after the addition of oligomycin to inhibit complex V, remained similar regardless of the exposure of adipocytes. In contrast, non-ATP-linked oxygen consumption tended to increase in cells exposed to irisin or Ex-4 compared to controls




Figure 5. Oxygen consumption measured by high resolution respirometry (Oxygraph-2k, OROBOROS Instruments) in Chub-S7 control cells and cells incubated with irisin (250 ng/ml, 24 h), exendin-4 (Ex-4, 100 nM, 24 h) or Ex-4 (100 nM, 24 h) + exendin-9 (Ex-4 + Ex-9, 100 nM, 24 h). **A** – Basal oxygen consumption rate (OCR) and non-mitochondrial OCR. **B** – Non-ATP and ATP-linked respiration. **C** – Maximum mitochondrial OCR and reserve capacity. Data are presented as mean ±SD (n = 3) and were analyzed using a t-test; *p < 0.05 compared to control

(Figure 5 B). Further analysis of mitochondrial respiratory states revealed significantly increased maximal mitochondrial OCR both in irisin and in Ex-4-treated cells after stimulation of electron transport chain uncoupling from ATP synthesis in mitochondria by FCCP. Reserve capacity, calculated by subtracting basal OCR from maximal oxygen consumption after the addition of FCCP, was found to slightly increase in a similar way after incubation with irisin or Ex-4 (Figure 5 C). Addition of exendin-9 to GLP-1RA caused OCR to be restored to control values, showing that the observed changes in mitochondrial oxygen consumption rates were dependent on Ex-4/GLP-1R interaction (Figure 5).

Intracellular ATP content

No changes in intracellular ATP content were observed in Chub-S7 cells exposed to irisin or Ex-4 (Figure 6). These results show that in the experiment, the increased mitochondrial oxygen consumption rate was not associated with raised ATP synthesis.

Discussion

Our previous work has shown that Ex-4 may affect the mitochondrial bioenergetics in human adipocytes by enhanced expression of sirtuins (1 and 3) [29]. Based on these results, in the current study, we also investigated the effect of GLP-1RA on secretion of selected adipokines (irisin, visfatin/NAMPT and adiponectin) related to the sirtuin pathway. It has been reported that adiponectin prevents mitochondrial dysfunction in a sirtuin-3 (SIRT3)-dependent manner [30]. Furthermore, SIRT3 is an NAD(+)-dependent deacetylase which functions in conjunction with mitochondrial NAMPT to promote cell survival following genotoxic stress [31].

Simental-Mendía *et al.* in a meta-analysis of randomized controlled trials reported an increase in adiponectin concentrations in the course of GLP-1RA therapy [32]. They observed a significant increase in serum adiponectin levels after liraglutide, while exenatide had no effect, which is consistent with our results. In our *in vitro* study, no significant changes in adiponectin secretion to the cell culture supernatant after incubation of Chub-S7 cells with Ex-4 were observed. The opposite results were obtained by Kim Chung *et al.* [33], who found that Ex-4 upregulated adiponectin synthesis in 3T3-L1 adipocytes though PKA expression and/or PKA activity. In our study, although adiponectin remained unchanged under Ex-4, secretion of another adipokine – irisin – was significantly increased. This finding is in line with the study by Liu *et al.* [20] demonstrating that exenatide significantly increased serum irisin levels in patients with T2D. These results suggest that




Figure 6. Intracellular ATP content in Chub-S7 control, irisin (250 ng/ml, 24 h) treated cells, exendin-4 (Ex-4, 100 nM, 24 h) treated cells and exendin-4 (100 nM, 24 h) + exendin-9 (Ex-4 + Ex-9, 100 nM, 24 h) treated cells. Results are presented as nmol ATP/mg of cell protein, as mean + SD measured in triplicate from three independent experiments, and were analyzed using a *t*-test

the upregulation of irisin might be a novel mechanism for the beneficial effects of exenatide in patients with T2D.

Visfatin is an adipocytokine with insulin mimetic activity whose enzymatic function is the same as NAMPT [34]. Our results showed that Ex-4 increased visfatin secretion to the culture medium and intracellular NAMPT level. A similar effect on visfatin was observed in other studies that showed that GLP-1 induced secretion of visfatin into the culture medium of 3T3-L1 adipocytes due to increased visfatin mRNA expression [35].

This study showed that Ex-4 significantly upregulated not only protein but also *NAMPT* gene expression. Similar results were obtained by Lee *et al.* [36] in an experiment on C57BL/6J mice, showing that *NAMPT* expression was induced by Ex-4 treatment. Furthermore, the data suggested that Ex-4 treatment may increase sirtuin expression via the NAD⁺ biosynthesis pathway. Indeed, our previous work showed that Ex-4 significantly increased expression of *SIRT1* [29]. Recent studies have demonstrated that NAMPT deficiency induces adipose tissue dysfunction and insulin resistance, and altered whole-body energy and glucose metabolism [37, 38]. These findings suggest that Ex-4 may have a beneficial effect on metabolic abnormalities by influencing postprandial glycemia also through an increase in expression of the *NAMPT* gene. Furthermore, NAMPT-mediated NAD⁺ biosynthesis and sirtuins in the intestine are critical for intestinal homeostasis, including GLP-1 production [39].

Our data showed that Ex-4 upregulated the expression of *UCP2*, responsible together with *UCP1* for heat generation and non-shivering thermogenesis in brown adipose tissue. In the presence of UCPs, a high respiratory rate occurs in the absence of ATP production. Uncoupling protein 2

plays a role in fatty acid and glucose metabolism and transportation of TCA cycle metabolites. The role of uncoupling proteins in various metabolic conditions, such as diabetes and obesity, has been reported [40].

Recent studies have demonstrated that *FNDC5* expression and secretion of irisin from adipocytes is lower in patients with obesity and T2D than in lean controls [41]. In our study, Ex-4 upregulated the expression of the *FNDC5* gene. This is particularly important, as irisin is known to suppress oxidative stress by retaining mitochondrial biogenesis and dynamics and exerts a protective effect by promoting SIRT3-dependent mitochondrial quality control [42, 43]. In addition, it has been shown that irisin treatment targets uncoupling protein 2 (UCP2) and activates the AMPK-Nrf2 pathway, substantially improving oxidative stress and mitochondrial dysfunction [44].

We also examined the influence of Ex-4 and irisin on mitochondrial functions in human adipocytes to compare the effects of these peptides. Our results showed that both irisin and Ex-4 increased maximum OCR. Recently, another study revealed a similar effect of irisin on the metabolic function of osteoclast progenitors during differentiation, where treatment with 10 ng/ml of irisin for 48 h significantly increased maximal respiration, associated with increased mitochondrial content shown by fluorescent imaging [45]. Furthermore, Jansen *et al.* [46] reported that the GLP-1 analog exenatide increased hepatic mitochondrial respiration in high-fat fed mice in various respiratory states, such as LEAK, OXPHOS, and ETS. In our study, both irisin and Ex-4 also independently increased non-ATP-linked OCR, while intracellular ATP content remain unchanged. This confirms our earlier report that increased mitochondrial OCR was accompanied by slightly decreased mitochondrial membrane potential but not excessive ATP synthesis in mature adipocytes exposed to Ex-4 [29]. Such subtle effects may reflect functional adaptations of mitochondria to conditions that require ATP generation or energy dissipation. Nutrient excess and physical activity are sensed at the organismal and cellular levels, activating hormonal, metabolite, and protein signaling that control mitochondrial-linked gene transcription and mRNA translation to enhance respiratory capacity [47]. Thus, mild effects of both the nutrient-sensitive peptides – the GLP-1RA exendin-4 and irisin – on mitochondrial respiration observed in our study may be a part of an adaptive response, preventing mitochondrial damage and subsequent proinflammatory and dysfunctional adipocytes.

To summarize, the present results showed that Ex-4 influences the expression of genes related to mitochondrial biogenesis, energy expenditure,

and mitochondrial uncoupling, including *FNDC5* coding for irisin, as well as mildly stimulating mitochondrial activity. The finding that changes in expression of mRNA and respective proteins are further reflected in mitochondrial bioenergetics is a strength of the study, as is the unique cell model. However, due to the limited data collected on mitochondrial metabolism, the results presented here should be considered as preliminary, providing a basis for further studies in animal models and clinical samples, supporting the hypothesis that irisin may mediate the action of GLP-1RAs. To better elucidate the action of irisin and confirm whether it mediates exendin-4 effects, it would also be interesting to perform experiments with simultaneous silencing of the *FNDC5* gene.

Although the study has yielded interesting results, it has some limitations. One shortcoming is that the *in vitro* Chub-S7 model derived from preadipocytes of a single obese individual does not reflect biological variability. It would be worthwhile to repeat the study on adipocytes from different donors, but this is difficult due to invasiveness and ethical considerations. On the other hand, such a model allows the detection of even small effects due to the high repeatability of the results. Indeed, the fold change in expression of selected genes is not impressive, and thus may reduce the strength of our observations. In our study, the observed effect of Ex-4 on mitochondrial activity was also relatively small. These modest effects may be due to the low level of GLP-1R expression in adipose tissue. Some authors have hypothesized that in humans, GLP-1R expression is more abundant in visceral adipose tissue (VAT), especially in obese subjects with a high insulin-resistant profile [48]. Although the expression of GLP-1R is well documented in human preadipocytes and adipocytes [48], the level of expression may be different in various types of adipocytes; therefore, it would be interesting to investigate the expression of GLP-1R at the mRNA or protein level in our cell model. In our research, we used the subcutaneous adipose tissue cell model (Chub-S7 cells) due to the small number of publications in this field. Further additional studies should be conducted with higher statistical power to confirm the observed associations.

In conclusion, stimulation of human adipocytes *in vitro* by the GLP-1RA Ex-4 enhanced the expression of irisin at the mRNA and protein levels. Ex-4 and irisin similarly increase energy expenditure in human adipocytes, a mechanism of action that is beneficial in the treatment of obesity. Given the limitations of the *in vitro* model using one human adipocyte cell line, further studies are necessary to confirm the hypothesis that nutrients, by stimulating the secretion of GLP-1, may influence the

expression of irisin and thus modulate the mitochondrial metabolism of adipocytes.

Funding

This research was funded by Jagiellonian University Medical College, grant number N41/DBS/000048 and K/ZDS/004496.

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1. Brauer M, Roth GA, Aravkin AV, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2162-203.
2. Horwitz A, Birk R. Adipose tissue hyperplasia and hypertrophy in common and syndromic obesity – the case of bbs obesity. *Nutrients* 2023; 15: 3445.
3. de Mello A, Costa AB, Engel JDG, Rezin GT. Mitochondrial dysfunction in obesity. *Life Sci* 2018; 192: 26-32.
4. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. *Endocr Rev* 2010; 31: 364-95.
5. Liu S, Cui F, Ning K, et al. Role of irisin in physiology and pathology. *Front Endocrinol (Lausanne)* 2022; 13: 962968.
6. Al-Amrani A, AbdelKarim M, AlZabin M, Alzoghbi M. Low expression of brown and beige fat genes in subcutaneous tissues in obese patients. *Arch Med Sci* 2019; 15: 1113-22.
7. Flori L, Testai L, Calderone V. The “Irisin System”: from biological roles to pharmacological and nutraceutical perspectives. *Life Sci* 2021; 267: 118954.
8. Korta P, Pocheć E, Mazur-Biały A. Irisin as a multifunctional protein: implications for health and certain diseases. *Medicina (Lithuania)* 2019; 55: 485.
9. Slate-Romano JJ, Yano N, Zhao TC. Irisin reduces inflammatory signaling pathways in inflammation-mediated metabolic syndrome. *Mol Cell Endocrinol* 2022; 552: 111676.
10. Bao JF, She QY, Hu PP, Jia N, Li A. Irisin, a fascinating field in our times. *Trends Endocrinol Metab* 2022; 33: 601-13.
11. Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. *Int J Obes* 2014; 38: 1538-44.
12. Wu T, Rayner CK, Horowitz M. Incretins. *Handb Exp Pharmacol* 2015; 233: 137-71.
13. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. *Diabetes Obes Metab* 2018; 20: 5-21.
14. Chia CW, Egan JM. Incretins in obesity and diabetes. *Ann N Y Acad Sci* 2020; 1461: 104-26.
15. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. *Diabetes Obes Metab* 2021; 23: 5-29.
16. Garber AJ. Novel GLP-1 receptor agonists for diabetes. *Expert Opin Investig Drugs* 2012; 21: 45-57.
17. Lorza-Gil E, Strauss OD, Ziegler E, et al. Incretin-responsive human pancreatic adipose tissue organoids: a functional model for fatty pancreas research. *Mol Metab* 2025; 91: 102067.
18. Zhao Q, Yang Y, Hu J, Shan Z, Wu Y, Lei L. Exendin-4 enhances expression of neurod1 and glut2 in insulin-producing cells derived from mouse embryonic stem cells. *Arch Med Sci* 2016; 12: 199-207.
19. Alhomoud IS, Talasaz AH, Chandrasekaran P, Brown R, Mehta A, Dixon DL. Incretin hormone agonists: current and emerging pharmacotherapy for obesity management. *Pharmacotherapy* 2024; 44: 738-52.
20. Liu J, Hu Y, Zhang H, Xu Y, Wang G. Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes. *J Diabetes Complications* 2016; 30: 1555-9.
21. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *Lancet Diabetes Endocrinol* 2016; 4: 525-36.
22. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. *Nat Rev Endocrinol* 2017; 13: 324-37.
23. Marrano N, Biondi G, Borrelli A, et al. Irisin and incretin hormones: similarities, differences, and implications in type 2 diabetes and obesity. *Biomolecules* 2021; 11: 286.
24. Darimont C, Zbinden I, Avanti O, et al. Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization. *Cell Death Differ* 2003; 10: 1025-31.
25. Gnaiger E, Renner-Sattler K. Phosphorylation Control Protocol with Intact Cells: ROUTINE, LEAK, ETS, ROX. *Mitochondrial Physiol Network* 2011: 1-14.
26. Dunham-Snary KJ, Sandel MW, Westbrook DG, Ballinger SW. A method for assessing mitochondrial bioenergetics in whole white adipose tissues. *Redox Biol* 2014; 2: 656-60.
27. Gnaiger E. Oroboros O2k-FluoRespirometer High-Resolution Respirometry O2k-Calibration by DatLab. *Mitochondrial Physiol Network* 2016; 19: 1-12.
28. Gnaiger E. Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and adenosine diphosphate supply. *Respir Physiol* 2001; 128: 277-97.
29. Góralaska J, Śliwa, A, Gruca, A, et al. Glucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes. *Acta Biochim Pol* 2017; 64: 423-9.
30. Zhang S, Wu X, Wang J, et al. Adiponectin/AdiopR1 signaling prevents mitochondrial dysfunction and oxidative injury after traumatic brain injury in a SIRT3 dependent manner. *Redox Biol* 2022; 54: 102390.
31. Shackelford R, Hirsh S, Henry K, Abdel-Mageed A, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. *Anticancer Res* 2013; 33: 3047-52.
32. Simental-Mendía LE, Sánchez-García A, Linden-Torres E, Simental-Mendía M. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials. *Br J Clin Pharmacol* 2021; 87: 4140-9.
33. Kim Chung LT, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin

- expression through protein kinase a pathway and prevents inflammatory adipokine expression. *Biochem Biophys Res Commun* 2009; 390: 613-8.
34. Sommer G, Garten A, Petzold S, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. *Clin Sci* 2008; 115: 13-23.
 35. Liu R, Ding X, Wang Y, Wang M, Peng Y. Glucagon-like peptide-1 upregulates visfatin expression in 3T3-L1 adipocytes. *Hormone Metab Res* 2013; 45: 646-51.
 36. Lee J, Hong SW, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. *PLoS One* 2012; 7: e31394.
 37. Yamaguchi S, Yoshino J. Adipose tissue NAD⁺ biology in obesity and insulin resistance: from mechanism to therapy. *BioEssays* 2017; 39: 10.1002/bies.201600227.
 38. Stromsdorfer KL, Yamaguchi S, Yoon MJ, et al. NAMPT-mediated NAD⁺ biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. *Cell Rep* 2016; 16: 1851-60.
 39. Nagahisa T, Kosugi S, Yamaguchi S. Interactions between intestinal homeostasis and NAD⁺ biology in regulating incretin production and postprandial glucose metabolism. *Nutrients* 2023; 15: 1494.
 40. Sreedhar A, Zhao Y. Uncoupling protein 2 and metabolic diseases. *Mitochondrion* 2017; 34: 135-40.
 41. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. *J Clin Endocrinol Metab* 2013; 98: E8769-78.
 42. Ge Y, Wu X, Cai Y, et al. FNDC5 prevents oxidative stress and neuronal apoptosis after traumatic brain injury through SIRT3-dependent regulation of mitochondrial quality control. *Cell Death Dis* 2024; 15: 364.
 43. Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and irisin. *Endocr Rev* 2021; 42: 436-56.
 44. Wen P, Sun Z, Yang D, et al. Irisin regulates oxidative stress and mitochondrial dysfunction through the UCP2-AMPK pathway in prion diseases. *Cell Death Dis* 2025; 16: 66.
 45. Estell E, Ichikawa T, Giffault P, Bonewald L, Spiegelman B, Rosen C. Irisin enhances mitochondrial function in osteoclast progenitors during differentiation. *Biomedicines* 2023; 11: 3311.
 46. Jansen KM, Dahdah N, Gama-Perez P, Schots PC, Larsen TS, Garcia-Roves PM. Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration. *Front Endocrinol (Lausanne)* 2023; 14: 1098391.
 47. Bennett CF, Latorre-Muro P, Puigserver P. Mechanisms of mitochondrial respiratory adaptation. *Nat Rev Mol Cell Biol* 2022; 23: 817-35.
 48. Ejarque M, Guerrero-Pérez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. *Sci Rep* 2019; 9: 6274.